Abstract：Objective To investigate the effects of dihydroartemisinin on RANKL-induced osteoclastogenesis.Methods Cell counting kit-8(CCK-8) was performed to exam the impact of dihydroartemisinin (1, 5, 10, 50, 100, 200 μmol/L) on viability of RAW264.7 cell line. RAW 264.7 cells were cultured with 50 ng/mL RANKL as well as dihydroartemisinin (5, 10, 50, 100 μmol/L) for 3 days to induce osteoclast formation, following with a TRAP staining. TRAP-positive cells with more than three nucleuses were counted. RAW264.7 cells were cultured with 50 ng/mL RANKL as well as 10 μmol/L and 100 μmol/L dihydroartemisinin for 24 h and total RNAs were extracted with Trizol reagent. The expressions of osteoclast-related genes were measured by real time-PCR, such as NFATc1, c-fos, Cathepsin K.Results Dihydroartemisinin (1, 5, 10, 50, 100 μmol/L) showed no significant cytotoxicity on RAW264.7 cell line for 24 h. Dihydroartemisinin (5, 10, 50, 100 μmol/L) inhibited RANKL-induced osteoclast formationin a dose-related manner. Dihydroartemisinincan (10, 100 μmol/L) down-regulated the expression of key osteoclast-forming gene NFATc1 and c-fos, with no significant influence on Cathepsin K.Conclusions Dihydroartemisinin is low cytotoxicity on RAW264.7 cell line. Dihydresoartemisinin can inhibit RANKL, induce osteoclastogenesis via down-regulating the expression of NFATc1 and c-fos. Dihydroartemisinin can be a potential pharmacological treatment for bone destruction disease.
Tando T, Sato Y, Miyamoto K, et al. Hif1α is required for osteoclast activation and bone loss in male osteoporosis[J]. Biochem Biophys Res Commun, 2016, 470(2): 391-396. DOI:10.1016/j.bbrc.2016.01.033
[2]
Brulefert K, CórdovaLA, Brulin B, et al. Pro-osteoclasticinvitroeffect of Polyethylene-likenanoparticles: Involvement in the pathogenesis of implantasepticloosening[J]. J Biomed Mater Res A, 2016, 104(11): 2649-2657. DOI:10.1002/jbm.a.35803
[3]
Gravallese EM, Manning C, Tsay A, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor[J]. Arthritis Rheum, 2000, 43(2): 250-258. DOI:10.1002/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P
[4]
Kim HK, Morgan-Bagley S, Kostenuik P. RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis[J]. J Bone Miner Res, 2006, 21(12): 1946-1954. DOI:10.1359/jbmr.060905
[5]
Lee NK, Choi YG, BaikJY, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation[J]. Blood, 2005, 106(3): 852-859. DOI:10.1182/blood-2004-09-3662
[6]
Wada T, Nakashima T, Hiroshi N, et al. RANKL-RANK signaling in osteoclastogenesis and bone disease[J]. Trends Mol Med, 2006, 12(1): 17-25. DOI:10.1016/j.molmed.2005.11.007
[7]
White NJ. Qinghaosu(artemisinin): theprice of success[J]. Science, 2008, 320(5874): 330-334. DOI:10.1126/science.1155165
[8]
Singh NP, Lai HC, Park JS, et al. Effects of artemisinin dimers on rat breast cancer cells in vitro and in vivo[J]. Anticancer Res, 2011, 31(12): 4111-4114
Shi C, Li H, Yang Y, et al. Anti-inflammatory and immunoregulatoryfunctions of artemisinin and itsderivatives[J]. Mediators Inflamm, 2015, 2015: 435713. DOI:10.1155/2015/435713
[11]
Tomomura M, Suzuki R, Shirataki Y, et al. Rhinacanthin C inhibits osteoclast differentiation and bone resorption: roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 signaling[J]. PLoS One, 2015, 10(6): e0130174. DOI:10.1371/journal.pone.0130174
[12]
Zhao Q, Wang X, Liu Y, et al. NFATc1: functions in osteoclasts[J]. Int J Biochem Cell Biol, 2010, 42(5): 576-579. DOI:10.1016/j.biocel.2009.12.018
[13]
Yamashita T, Yao Z, Li F, et al. NF-kappa B p50 and p52 regulate receptor activator of NF-kappa B ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1[J]. J Biol Chem, 2007, 282(25): 18245-18253. DOI:10.1074/jbc.M610701200
[14]
Mandelin J, Li TF, Liljestr?m M, et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement[J]. J Bone Joint Surg Br, 2003, 85(8): 1196-1201. DOI:10.1302/0301-620x.85b8.13311
[15]
Jabbar S, Drury J, Fordham JN, et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis[J]. J Clin Pathol, 2011, 64(4): 354-357. DOI:10.1136/jcp.2010.086595
[16]
GeusensPP, LandewéRB, Garnero P, et al. The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction[J]. Arthritis Rheum, 2006, 54(6): 1772-1777. DOI:10.1002/art.21896
[17]
Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer[J]. Clinical cancer research, 2006, 12(4): 1221-1228. DOI:10.1158/1078-0432.CCR-05-1933
[18]
Xiu Y, Xu H, Zhao C, et al. Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation[J]. J Clin Invest, 2014, 124(1): 297-310. DOI:10.1172/JCI66947
[19]
Le Chapelain C, Groll M. Rational design of proteasome inhibitors as antimalarial drugs[J]. Angew Chem Int Ed Engl, 2016, 55(22): 6370-6372. DOI:10.1002/anie.201602519
[20]
Kara FM, Chitu V, Sloane J, et al. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function[J]. FASEB J, 2010, 24(7): 2325-2333. DOI:10.1096/fj.09-147447
[21]
Hara Y, Yamawaki H, Shimada M, et al. Anticholinergic effects of artemisinin, an antimalarial drug, in isolated guinea pig heart preparations[J]. J Vet Med Sci, 2007, 69(7): 697-702. DOI:10.1292/jvms.69.697
2017, Vol. 22 
